NF‐κB and the link between inflammation and cancer

Immunological Reviews - Tập 246 Số 1 - Trang 379-400 - 2012
Joseph A. DiDonato1, Frank Mercurio2, Michael Karin3
1Cleveland Clinic Foundation, Department of Cell Biology, Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, USA.
2BioTheryX Inc., San Diego, CA, USA
3Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California at San Diego, USA.

Tóm tắt

Summary:  The nuclear factor‐κB (NF‐κB) transcription factor family has been considered the central mediator of the inflammatory process and a key participant in innate and adaptive immune responses. Coincident with the molecular cloning of NF‐κB/RelA and identification of its kinship to the v‐Rel oncogene, it was anticipated that NF‐κB itself would be involved in cancer development. Oncogenic activating mutations in NF‐κB genes are rare and have been identified only in some lymphoid malignancies, while most NF‐κB activating mutations in lymphoid malignancies occur in upstream signaling components that feed into NF‐κB. NF‐κB activation is also prevalent in carcinomas, in which NF‐κB activation is mainly driven by inflammatory cytokines within the tumor microenvironment. Importantly, however, in all malignancies, NF‐κB acts in a cell type‐specific manner: activating survival genes within cancer cells and inflammation‐promoting genes in components of the tumor microenvironment. Yet, the complex biological functions of NF‐κB have made its therapeutic targeting a challenge.

Từ khóa


Tài liệu tham khảo

10.1016/0092-8674(91)90320-X

10.1007/0-306-48158-8_10

10.1038/nrc780

10.1016/j.cell.2010.01.025

10.1038/ni.2060

10.1126/science.274.5288.782

10.1016/S0092-8674(00)81375-6

10.1126/science.274.5288.787

10.1126/science.274.5288.784

10.1016/S1359-6101(00)00018-6

10.1038/sj.onc.1204535

10.1016/S0140-6736(00)04046-0

10.1038/nature07205

10.1038/nature04870

10.1101/cshperspect.a000141

10.1016/j.cell.2007.03.052

10.1038/nature05656

10.1016/j.ccr.2007.07.004

10.1016/j.ccr.2007.07.003

10.1038/nature09837

10.1016/0092-8674(86)90346-6

10.1016/0092-8674(86)90807-X

10.1016/0092-8674(88)90382-0

10.1126/science.3140380

10.1016/0092-8674(91)90022-Q

10.1016/0092-8674(95)90511-1

Link E, 1992, Purified I kappa B‐beta is inactivated upon dephosphorylation, J Biol Chem, 267, 239, 10.1016/S0021-9258(18)48485-2

10.1146/annurev.immunol.14.1.649

10.1101/gad.9.22.2723

10.1016/0092-8674(87)90611-8

10.1038/329648a0

10.1016/0092-8674(88)90076-1

10.1002/j.1460-2075.1989.tb03528.x

10.1002/j.1460-2075.1989.tb03399.x

10.1073/pnas.85.13.4700

10.1038/348076a0

10.1016/0092-8674(90)90276-K

10.1016/0092-8674(90)90275-J

10.1089/dna.1992.11.523

10.1016/0092-8674(91)90285-7

10.1038/352733a0

10.1128/MCB.12.2.685

10.1016/0092-8674(92)90353-E

10.1101/gad.7.4.705

10.1111/j.1600-065X.2012.01102.x

10.1126/science.270.5234.286

10.1126/science.270.5234.283

10.1128/MCB.15.5.2689

10.1016/0092-8674(90)90396-V

10.1128/MCB.15.2.943

10.1038/365182a0

10.1128/MCB.13.6.3301

10.1073/pnas.90.6.2532

Cordle SR, 1993, Lipopolysaccharide induces phosphorylation of MAD3 and activation of c‐Rel and related NF‐kappa B proteins in human monocytic THP‐1 cells, J Biol Chem, 268, 11803, 10.1016/S0021-9258(19)50271-X

10.1093/nar/21.22.5059

10.1128/MCB.15.3.1302

10.1101/gad.9.13.1586

10.1111/j.1600-065X.2012.01098.x

10.1128/MCB.15.5.2413

10.1073/pnas.92.24.11259

10.1128/MCB.16.4.1295

Connelly MA, 1995, CHUK, a new member of the helix‐loop‐helix and leucine zipper families of interacting proteins, contains a serine‐threonine kinase catalytic domain, Cell Mol Biol Res, 41, 537

10.1038/41493

10.1016/S0092-8674(00)80344-X

10.1016/S0092-8674(00)80406-7

10.1126/science.278.5339.860

10.1038/26261

10.1128/MCB.19.2.1526

10.1016/S0092-8674(00)81466-X

10.1126/science.284.5412.316

10.1101/gad.13.10.1322

10.1084/jem.189.11.1839

10.1126/science.284.5412.321

10.1016/S1074-7613(00)80042-4

10.1016/S1097-2765(00)80262-2

10.1101/gad.14.7.854

10.1016/S1097-2765(00)80263-4

10.1038/35013114

10.1038/85837

10.4049/jimmunol.165.2.804

10.1016/0092-8674(95)90416-6

10.4049/jimmunol.158.11.5211

10.4049/jimmunol.167.4.1909

10.1126/science.1062677

10.1038/cr.2010.177

10.1038/sj.onc.1203237

10.1016/S0092-8674(00)80957-5

10.1016/S1097-2765(05)00086-9

10.1093/emboj/19.23.6351

10.1034/j.1600-065X.2000.00615.x

10.1084/jem.20020907

10.1126/stke.3572006re13

10.1101/cshperspect.a003350

10.1084/jem.194.12.1861

10.1038/nature04687

10.1126/science.1153629

10.1038/nature09671

10.1101/cshperspect.a000109

10.1146/annurev.immunol.021908.132641

10.1073/pnas.0805186105

10.1073/pnas.0806491106

10.1101/gr.110684.110

10.1038/nature07943

10.1073/pnas.0706728104

10.1038/nature09495

10.1038/nature09387

10.1038/nature08782

10.1007/978-0-387-73898-7_9

10.3109/07853890903405753

10.1016/j.cell.2004.07.013

10.1038/nature02924

10.1126/science.275.5307.1787

10.1136/gut.39.1.87

10.1016/S1044-579X(02)00128-1

10.1016/j.immuni.2004.07.020

10.1016/j.ccr.2009.01.001

10.1016/j.ccr.2009.01.002

10.1084/jem.20082683

Mauad TH, 1994, Mice with homozygous disruption of the mdr2 P‐glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis, Am J Pathol, 145, 1237

10.1016/j.cell.2005.04.014

10.1126/science.1140485

10.1016/j.ccr.2009.12.048

10.1016/j.ccr.2006.12.016

10.1038/ng2033

10.1073/pnas.0603499103

10.1016/j.ccr.2008.06.016

10.1016/j.cell.2004.12.041

10.1073/pnas.92.8.3439

Gingrich JR, 1996, Metastatic prostate cancer in a transgenic mouse, Cancer Res, 56, 4096

Gasparian AV, 2002, The role of IKK in constitutive activation of NF‐kappaB transcription factor in prostate carcinoma cells, J Cell Sci, 115, 141, 10.1242/jcs.115.1.141

10.1002/jcb.20721

10.1084/jem.185.11.1897

10.1016/S1074-7613(00)80307-6

10.1128/MCB.16.9.5015

10.1083/jcb.134.1.13

10.1126/science.7777860

10.1126/science.274.5291.1383

10.1038/sj.onc.1201088

Esslinger CW, 1997, Abnormal T lymphocyte development induced by targeted overexpression of IkappaB alpha, J Immunol, 158, 5075, 10.4049/jimmunol.158.11.5075

10.1084/jem.189.1.145

10.1038/nrm2083

10.1016/j.molcel.2007.04.006

10.1038/nature01283

10.1016/j.cell.2008.03.038

10.1073/pnas.0909781107

10.1016/j.ccr.2010.03.021

10.1016/S1470-2045(11)70202-9

10.2174/156800911794519752

10.1016/S0074-7696(08)61873-2

10.1056/NEJM199704103361506

10.1016/j.cell.2007.07.009

10.1038/ni.1976

10.1038/cr.2008.30

10.1111/j.1600-065X.2011.01088.x

10.1111/j.1349-7006.2008.00750.x

10.1074/jbc.274.36.25245

10.1111/j.1600-065X.2012.01105.x

10.1182/blood-2004-08-3247

Okazaki Y, 2005, Effect of nuclear factor‐kappaB inhibition on rheumatoid fibroblast‐like synoviocytes and collagen induced arthritis, J Rheumatol, 32, 1440

10.1152/ajpheart.00776.2007

10.1038/sj.leu.2404614

10.1038/nrd1279

10.1517/13543784.2011.559162

10.1007/978-3-642-01222-8_1

10.1517/14728222.12.7.883

10.1158/0008-5472.CAN-09-3912

10.1074/jbc.M301598200

10.1038/sj.embor.7400234

10.1016/j.tcb.2009.05.006

10.1158/1078-0432.CCR-08-0124

10.1016/S0092-8674(04)00302-2

10.1016/j.cll.2010.10.001

10.1158/1078-0432.CCR-10-3310

10.1016/S1471-4914(02)02315-8

Hideshima T, 2001, The proteasome inhibitor PS‐341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells, Cancer Res, 61, 3071

10.1093/jnci/djr160

10.1016/0955-0674(95)80031-X

10.1016/j.cell.2010.11.016

10.1016/S0092-8674(00)81058-2

10.1073/pnas.92.23.10599

10.1016/S0092-8674(94)90482-0

10.1093/emboj/16.21.6486

10.1038/25159

Jobin C, 1998, Inhibition of proinflammatory molecule production by adenovirus‐mediated expression of a nuclear factor kappaB super‐repressor in human intestinal epithelial cells, J Immunol, 160, 410, 10.4049/jimmunol.160.1.410

10.1038/nrc2396

10.1074/jbc.274.42.29591

10.1128/MCB.23.1.402-413.2003

10.1093/emboj/19.11.2580

10.1634/theoncologist.12-9-1124

10.1074/jbc.M112210200

10.1158/1078-0432.CCR-04-1162

10.1128/MCB.24.18.8184-8194.2004

10.1093/jnci/djh219

10.1038/nature02082

Soldatenkov VA, 1999, Inhibition of homologue of Slimb (HOS) function sensitizes human melanoma cells for apoptosis, Cancer Res, 59, 5085

10.1158/0008-5472.CAN-04-2597

10.1126/science.1130276

10.1128/MCB.00620-06

10.1073/pnas.0501873102

10.1002/cncr.22983

10.1002/path.1378

10.1038/sj.onc.1202653

10.1101/gad.13.3.270

10.1016/j.cell.2006.10.018

10.1016/S1097-2765(01)00241-6

10.1016/S1097-2765(01)00242-8

10.1016/j.bbrc.2008.01.166

10.2174/156652410791316968

Hanahan D, 2000, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

10.1172/JCI11830

10.1016/j.biocel.2009.12.016

10.1016/S0140-6736(00)49915-0

10.1016/j.bbagrm.2010.05.004

10.1126/science.1154986

10.1038/nature09853

Thông tin
Thông tin xuất bản

Immunological Reviews

Tập 246 Số 1

379-400

Thông tin tác giả